Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||clear cell renal cell carcinoma||not applicable||Nivolumab||Phase II||Actionable||In a Phase II trial (HCRN GU16-260), Opdivo (nivolumab) treatment resulted in an objective response rate of 29.3% (34/117, 5 complete responses, 29 partial responses) and stable disease in 40.2% (47/117) of patients with treatment naive clear cell renal cell carcinoma, with a median duration of response of 13.8 months and a median progression-free survival of 7.4 months (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 5006-5006; NCT03117309).||detail...|
|PubMed Id||Reference Title||Details|
|Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).||Full reference...|